Medicine and Dentistry
(3 Iodobenzyl)guanidine I 131
100%
Bystander Effect
96%
Noradrenalin
88%
Low Drug Dose
77%
DNA Damage
64%
Drug Megadose
58%
Radiation Therapy
57%
Gamma Irradiation
56%
Combination Therapy
52%
Radiosensitization
48%
Bortezomib
48%
Xenograft
48%
(3 Iodobenzyl)guanidine
48%
Iodine 131
48%
Proteasome Inhibitor
48%
Topotecan
48%
Toxicity
48%
Poly ADP Ribose Polymerase
48%
Dose Calculation
48%
Base Excision Repair
48%
Linear Energy Transfer
48%
Therapeutic Procedure
40%
Radiation Therapy
32%
Radiation
24%
Radiopharmaceutical
19%
Iodine 123
19%
Radioisotope
19%
Cytotoxicity
18%
Benzyloxycarbonylleucylleucylleucinal
18%
Dose Response
17%
X Irradiation
17%
Topoisomerase Inhibitor
16%
Clinical Trial
16%
Ganglioneuroblastoma
16%
In Vitro
16%
Poly ADP Ribose Polymerase
16%
Spontaneous Remission
16%
Patient
16%
Clonogenic Assay
14%
Proteasome
12%
Auger Electron Spectroscopy
9%
Cell Death
9%
Glioma Cell Line
9%
DNA Strand Breakage
9%
Norepinephrine Transporter
8%
Cell Cycle
8%
Cancer
8%
DNA Repair
8%
Programmed Cell Death
8%
Malignant Neoplasm
8%
Radiopharmaceutical Agent
8%
Expression Vector
6%
Ganglioglioma
6%
Therapeutic Modality
6%
Pharmacology, Toxicology and Pharmaceutical Science
Disulfiram
96%
Neoplasm
63%
Malignant Neoplasm
60%
Noradrenalin
54%
Radiation
51%
Radioisotope
51%
Toxicity
48%
Copper
48%
Bortezomib
48%
Proteasome Inhibitor
48%
X Irradiation
48%
Double Stranded DNA
48%
(3 Iodobenzyl)guanidine I 131
48%
Iobenguane
39%
Topotecan
30%
Cytotoxicity
24%
Benzyloxycarbonylleucylleucylleucinal
18%
Radiopharmaceutical Agent
15%
Glioma
15%
DNA (Apurinic or Apyrimidinic Site) Lyase
12%
Gel Electrophoresis
12%
Cell Culture
12%
DNA Topoisomerase Inhibitor
12%
Flow Cytometry
12%
Combination Therapy
12%
Propidium Iodide
12%
Neoplasm
12%
Single Stranded DNA
12%
Comet Assay
9%
Tumor Growth
9%
Cytotoxicity
9%
Gamma Irradiation
8%
Neuroendocrine Tumor
6%
Proteasome
6%
Radiosensitizing Agent
6%
Tenidap
6%
Element
6%
Enalapril Maleate
6%
(3 Iodobenzyl)guanidine I 131
6%
Colorectal Cancer
6%
High-Throughput Screening
6%